HAT for the Treatment of Sepsis Associated With NASTI

  • participants needed
  • sponsor
    Ascension Via Christi Hospitals Wichita, Inc.
Updated on 2 February 2023


Evaluate the impact of HAT therapy versus placebo in the treatment of patients with an acute NSTI and sepsis.


Primary outcome:

  1. Hospital survival

Secondary outcomes:

  1. Duration of vasopressor therapy
  2. Requirement for renal replacement therapy in patients with Acute Kidney Injury (AKI)
  3. ICU length of stay (LOS)
  4. Change in serum procalcitonin (PCT) over first 72 hours
  5. Change in SOFA score over first 72 hours (measured as SOFA score daily for four days, with day one being admission, then 3 days after, totaling 4 days of treatment with HAT)
  6. Procalcitonin clearance (formula = initial PCT - 72 hour PCT divided by initial PCT x 100)
  7. Number of wound related surgeries
  8. Wound status at time of hospital discharge:
  9. Open
  10. Closed

Condition Necrotizing Soft Tissue Infection, Sepsis
Treatment Placebo, HAT, HAT
Clinical Study IdentifierNCT05157360
SponsorAscension Via Christi Hospitals Wichita, Inc.
Last Modified on2 February 2023

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note